Actinium Pharmaceuticals announced preclinical ATNM-400 data on October 16, 2026, showing antitumor activity across lung, colorectal and ovarian cancer models. The findings support research into the investigational radiotherapy both alone and alongside established treatments, but do not establish effectiveness in patients with those cancers.
Key Takeaways
- The studies showed activity across three solid-tumor settings, including treatment-resistant models.
- Actinium is pursuing both standalone and combination approaches for ATNM-400.
- The October 16 announcement preceded three scheduled presentations at EANM 2026 in Vienna.
Table of Contents
- ATNM-400 data broaden the solid-tumor research case
- Colorectal and ovarian studies test different treatment roles
- Conference presentations are the next scheduled milestone
- Conclusion
ATNM-400 data broaden the solid-tumor research case
ATNM-400 uses the alpha-emitting isotope Actinium-225. Actinium’s EANM presentation announcement describes preclinical findings that expand the program’s evidence across multiple cancer types, complementing its ongoing clinical development in metastatic castration-resistant prostate cancer.
In non-small cell lung cancer, the company reported activity with ATNM-400 alone and enhanced activity when combined with KRAS or ALK inhibitors, including in resistant models. These findings build on earlier EGFR-mutant results.
For Actinium, the research supports an effort to develop the treatment beyond a single mutation-defined lung cancer population. That remains a development objective rather than a demonstrated benefit across patient groups.
| Item | Details |
|---|---|
| Lung cancer presentation | Abstract EPS-149; oral presentation in the Translational Imaging and Therapy session. |
| Colorectal cancer models | SW620 xenografts for standalone activity; HCT15 xenografts for combination findings. |
| Colorectal cancer e-poster | Abstract EP-0163. |
| Ovarian cancer e-poster | Abstract EP-0176. |
Colorectal and ovarian studies test different treatment roles
The colorectal cancer studies showed standalone activity and stronger activity in combination with bevacizumab plus oxaliplatin. The combination findings included a model with moderate target expression and a limited response to the established two-drug regimen.
In ovarian cancer models, ATNM-400 alone produced durable antitumor activity, including in tumors resistant to bevacizumab. Actinium said these findings support further evaluation as a standalone treatment in recurrent disease and in combinations with standard therapies.
The distinction matters: the studies do not point to one uniform regimen across all three cancers. Instead, they provide a rationale for evaluating different treatment combinations and standalone uses.
Conference presentations are the next scheduled milestone
The company scheduled one oral presentation and two e-posters for the 39th Annual Congress of the European Association of Nuclear Medicine, taking place October 17–21, 2026, in Vienna, Austria. October 16 was the announcement date, not the date the findings were presented.
The lung cancer oral presentation was scheduled for October 19 in a session running from 4:45 to 6:15 p.m. CEST. The colorectal and ovarian studies were designated as e-posters.
These are preclinical research updates, not clinical results in the three highlighted cancer types or regulatory approvals. Their relevance to Actinium’s pipeline is the additional rationale for further development; whether the activity translates into patient benefit remains unproven.
Conclusion
The next confirmed milestone was the EANM presentation program, including the October 19 lung cancer session. The findings broaden Actinium’s research rationale for ATNM-400, while clinical benefit in these cancer types remains to be established.
Read More News
Disclaimer
This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.
